Xencor Stock Price, News & Analysis (NASDAQ:XNCR)

$21.35 0.17 (0.80 %)
(As of 11/20/2017 04:00 PM ET)
Previous Close$21.18
Today's Range$20.87 - $21.48
52-Week Range$18.55 - $29.38
Volume94,400 shs
Average Volume213,943 shs
Market Capitalization$1.00261 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.08

About Xencor (NASDAQ:XNCR)

Xencor logoXencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases. It is also developing a pipeline of bispecific antibody candidates using its heterodimer Fc bispecific technology: XmAb14045, which is in a Phase I trial for the treatment of acute myeloid leukemia (AML); XmAb13676, which is in a Phase I trial for the treatment of B-cell malignancies; XmAb18087, which is in preclinical development for the treatment of neuroendocrine tumors, and XmAb20717, which is in preclinical development for the treatment of various cancers and is its dual checkpoint inhibitor.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: NASDAQ:XNCR
  • CUSIP: N/A
  • Web: www.xencor.com
Debt:
  • Current Ratio: 2.17%
  • Quick Ratio: 2.17%
Sales & Book Value:
  • Annual Sales: $87.52 million
  • Price / Sales: 11.46
  • Cash Flow: $0.60 per share
  • Price / Cash: 35.53
  • Book Value: $6.87 per share
  • Price / Book: 3.11
Profitability:
  • Trailing EPS: ($1.00)
  • Net Income: $23.62 million
  • Net Margins: -148.29%
  • Return on Equity: -15.26%
  • Return on Assets: -11.11%
Misc:
  • Employees: 83
  • Outstanding Shares: 46,960,000
 

Frequently Asked Questions for Xencor (NASDAQ:XNCR)

What is Xencor's stock symbol?

Xencor trades on the NASDAQ under the ticker symbol "XNCR."

How were Xencor's earnings last quarter?

Xencor, Inc. (NASDAQ:XNCR) announced its quarterly earnings results on Tuesday, August, 2nd. The biopharmaceutical company reported $1.13 earnings per share for the quarter, topping the consensus estimate of ($0.18) by $1.31. The biopharmaceutical company had revenue of $66 million for the quarter, compared to the consensus estimate of $7.43 million. Xencor had a negative return on equity of 15.26% and a negative net margin of 148.29%. View Xencor's Earnings History.

Where is Xencor's stock going? Where will Xencor's stock price be in 2017?

5 analysts have issued 12 month target prices for Xencor's shares. Their predictions range from $21.00 to $36.00. On average, they expect Xencor's share price to reach $30.25 in the next year. View Analyst Ratings for Xencor.

What are Wall Street analysts saying about Xencor stock?

Here are some recent quotes from research analysts about Xencor stock:

  • 1. According to Zacks Investment Research, "Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California. " (11/11/2017)
  • 2. Instinet analysts commented, "We are initiating on XNCR with a Neutral rating and a $21 target price. We recommend stepping to the sidelines in 2017, as we anticipate that XNCR shares will trade flat relative to the biotechnology index over the next 12 months. We note that several near-term catalysts are likely already 'baked in' the current valuation, particularly for the '5871 IgG4- RD program. We believe that a key catalyst'meaningful data for XNCR's bispecific assets'is likely to lead to upside, but that it will occur beyond our 12-month horizon." (3/1/2017)

Who are some of Xencor's key competitors?

Who are Xencor's key executives?

Xencor's management team includes the folowing people:

  • Bassil I. Dahiyat Ph.D., President, Chief Executive Officer, Founder, Director (Age 46)
  • John R. Desjarlais Ph.D., Senior Vice President, Research and Chief Scientific Officer (Age 52)
  • Paul Foster M.D., Senior Vice President, Chief Medical Officer (Age 63)
  • John J. Kuch, Vice President - Finance (Age 57)
  • Edgardo Baracchini Jr. Ph.D., Chief Business Officer (Age 57)
  • A. Bruce Montgomery M.D., Lead Independent Director (Age 63)
  • Kevin C. Gorman Ph.D., Independent Director (Age 58)
  • Kurt A. Gustafson, Independent Director (Age 49)
  • Yujiro S. Hata, Independent Director (Age 43)

Who owns Xencor stock?

Xencor's stock is owned by a variety of of institutional and retail investors. Top institutional investors include JPMorgan Chase & Co. (0.61%), Dimensional Fund Advisors LP (0.55%), Cannell Peter B & Co. Inc. (0.43%), Bank of New York Mellon Corp (0.42%), Schwab Charles Investment Management Inc. (0.40%) and Artal Group S.A. (0.21%). Company insiders that own Xencor stock include Bassil I Dahiyat, Bruce L A Carter, Edgardo Baracchini Jr, Edgardo Baracchini, Jr, John J Kuch, John R Desjarlais, John S Stafford III and Paul A Foster. View Institutional Ownership Trends for Xencor.

Who sold Xencor stock? Who is selling Xencor stock?

Xencor's stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Cannell Peter B & Co. Inc., Schwab Charles Investment Management Inc., New York State Common Retirement Fund, California State Teachers Retirement System, Dimensional Fund Advisors LP, JPMorgan Chase & Co. and Bank of New York Mellon Corp. Company insiders that have sold Xencor company stock in the last year include Bruce L A Carter, Edgardo Baracchini Jr, John J Kuch and John S Stafford III. View Insider Buying and Selling for Xencor.

Who bought Xencor stock? Who is buying Xencor stock?

Xencor's stock was acquired by a variety of institutional investors in the last quarter, including Artal Group S.A., Point72 Asset Management L.P., GSA Capital Partners LLP, Los Angeles Capital Management & Equity Research Inc., TD Asset Management Inc., Prudential Financial Inc., Principal Financial Group Inc. and Virginia Retirement Systems ET AL. View Insider Buying and Selling for Xencor.

How do I buy Xencor stock?

Shares of Xencor can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Xencor's stock price today?

One share of Xencor stock can currently be purchased for approximately $21.35.

How big of a company is Xencor?

Xencor has a market capitalization of $1.00261 billion and generates $87.52 million in revenue each year. The biopharmaceutical company earns $23.62 million in net income (profit) each year or ($1.00) on an earnings per share basis. Xencor employs 83 workers across the globe.

How can I contact Xencor?

Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The biopharmaceutical company can be reached via phone at 626-305-5900 or via email at [email protected]


MarketBeat Community Rating for Xencor (NASDAQ XNCR)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  206 (Vote Outperform)
Underperform Votes:  103 (Vote Underperform)
Total Votes:  309
MarketBeat's community ratings are surveys of what our community members think about Xencor and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Xencor (NASDAQ:XNCR)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 2 Hold Ratings, 3 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $30.25 (41.69% upside)

Consensus Price Target History for Xencor (NASDAQ:XNCR)

Price Target History for Xencor (NASDAQ:XNCR)

Analysts' Ratings History for Xencor (NASDAQ:XNCR)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/12/2017Piper Jaffray CompaniesReiterated RatingBuy$35.00N/AView Rating Details
10/23/2017Canaccord GenuitySet Price TargetBuy$36.00N/AView Rating Details
6/16/2017WedbushReiterated RatingOutperform$29.00LowView Rating Details
3/1/2017InstinetInitiated CoverageNeutral -> Neutral$21.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageNeutralN/AView Rating Details
11/3/2016Leerink SwannReiterated RatingBuy$26.00N/AView Rating Details
5/2/2016Oppenheimer Holdings, Inc.Reiterated RatingBuyN/AView Rating Details
12/22/2015FBR & CoReiterated RatingBuy$20.00N/AView Rating Details
(Data available from 11/20/2015 forward)

Earnings

Earnings History and Estimates Chart for Xencor (NASDAQ:XNCR)

Earnings by Quarter for Xencor (NASDAQ:XNCR)

Earnings History by Quarter for Xencor (NASDAQ XNCR)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2017Q2 2017($0.25)($0.15)$8.15 million$13.34 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.25)($0.31)$8.15 million$4.34 millionViewListenView Earnings Details
8/2/2016Q216($0.18)$1.13$7.43 million$66.00 millionViewN/AView Earnings Details
5/2/2016Q116($0.27)($0.16)$3.50 million$7.30 millionViewN/AView Earnings Details
3/7/2016Q415($0.30)$0.19$2.50 million$21.80 millionViewN/AView Earnings Details
11/3/2015Q315($0.17)($0.25)$3.57 million$3.50 millionViewN/AView Earnings Details
8/4/2015Q215($0.18)($0.22)$1.90 million$1.01 millionViewN/AView Earnings Details
5/4/2015Q115($0.17)($0.19)$1.90 million$1.49 millionViewListenView Earnings Details
2/19/2015($0.22)($0.04)$1.33 million$5.66 millionViewN/AView Earnings Details
11/10/2014Q3 14($0.19)($0.20)$1.50 million$0.85 millionViewN/AView Earnings Details
7/31/2014($0.19)($0.16)$0.82 millionViewN/AView Earnings Details
5/14/2014Q1 14($0.16)($0.12)$1.71 million$2.20 millionViewN/AView Earnings Details
3/19/2014Q413($0.14)($0.24)$1.71 million$1.70 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Xencor (NASDAQ:XNCR)
2017 EPS Consensus Estimate: ($0.97)
2018 EPS Consensus Estimate: ($1.83)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.22)($0.17)($0.20)
Q2 20172($0.29)($0.19)($0.24)
Q3 20172($0.32)($0.23)($0.28)
Q4 20172($0.27)($0.25)($0.26)
Q1 20181($0.43)($0.43)($0.43)
Q2 20181($0.45)($0.45)($0.45)
Q3 20181($0.48)($0.48)($0.48)
Q4 20181($0.47)($0.47)($0.47)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Xencor (NASDAQ:XNCR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Xencor (NASDAQ XNCR)

Insider Ownership Percentage: 4.14%
Institutional Ownership Percentage: 76.97%
Insider Trades by Quarter for Xencor (NASDAQ:XNCR)
Institutional Ownership by Quarter for Xencor (NASDAQ:XNCR)

Insider Trades by Quarter for Xencor (NASDAQ XNCR)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/10/2017John S Stafford IIIMajor ShareholderBuy324$19.90$6,447.60View SEC Filing  
11/8/2017John S Stafford IIIMajor ShareholderBuy3,400$19.89$67,626.00View SEC Filing  
11/6/2017John S Stafford IIIMajor ShareholderBuy305$19.92$6,075.60View SEC Filing  
11/2/2017John S Stafford IIIMajor ShareholderBuy50,000$19.58$979,000.00View SEC Filing  
10/31/2017John S Stafford IIIMajor ShareholderBuy13,700$19.81$271,397.00View SEC Filing  
10/27/2017John S Stafford IIIMajor ShareholderBuy150,000$19.81$2,971,500.00View SEC Filing  
10/25/2017John S Stafford IIIMajor ShareholderBuy24,653$20.01$493,306.53View SEC Filing  
8/22/2017John S Stafford IIIMajor ShareholderBuy41,016$19.69$807,605.04View SEC Filing  
8/18/2017John S Stafford IIIMajor ShareholderBuy43,500$19.93$866,955.00View SEC Filing  
8/17/2017John S Stafford IIIMajor ShareholderBuy79,035$20.47$1,617,846.45View SEC Filing  
8/16/2017John S Stafford IIIMajor ShareholderBuy25,000$20.96$524,000.00View SEC Filing  
8/11/2017John S Stafford IIIMajor ShareholderBuy27,000$21.13$570,510.00View SEC Filing  
6/28/2017John S Stafford IIIMajor ShareholderBuy6,000$19.94$119,640.00View SEC Filing  
6/16/2017John S Stafford IIIMajor ShareholderBuy1,500$19.67$29,505.00View SEC Filing  
6/14/2017Bruce L A CarterDirectorSell20,000$20.61$412,200.00View SEC Filing  
6/2/2017Bruce L A CarterDirectorSell2,366$22.00$52,052.00View SEC Filing  
5/26/2017Bruce L A CarterDirectorSell12,400$22.19$275,156.00View SEC Filing  
5/2/2017Edgardo Baracchini JrInsiderSell10,568$26.01$274,873.68View SEC Filing  
4/27/2017Edgardo Baracchini JrInsiderSell904$26.04$23,540.16View SEC Filing  
3/16/2017John J. KuchVPSell15,000$24.42$366,300.00View SEC Filing  
3/8/2017Edgardo Baracchini JrInsiderSell1,821$25.00$45,525.00View SEC Filing  
12/6/2016John S Stafford IIIMajor ShareholderSell63,061$27.71$1,747,420.31View SEC Filing  
9/28/2016Edgardo Baracchini JrInsiderSell10,000$25.35$253,500.00View SEC Filing  
9/27/2016John S Stafford IIIMajor ShareholderSell40,000$25.72$1,028,800.00View SEC Filing  
9/2/2016Edgardo Baracchini JrInsiderSell10,000$21.06$210,600.00View SEC Filing  
8/30/2016Bassil I DahiyatInsiderSell40,000$21.80$872,000.00View SEC Filing  
8/26/2016John S Stafford IIIMajor ShareholderSell24,351$21.48$523,059.48View SEC Filing  
8/24/2016John J KuchVPSell25,000$21.95$548,750.00View SEC Filing  
8/23/2016John R DesjarlaisVPSell16,294$21.73$354,068.62View SEC Filing  
8/23/2016John S Stafford IIIMajor ShareholderSell96,828$21.73$2,104,072.44View SEC Filing  
8/16/2016Bassil I DahiyatInsiderSell45,886$22.06$1,012,245.16View SEC Filing  
8/15/2016Bruce L A CarterDirectorSell3,400$22.67$77,078.00View SEC Filing  
8/15/2016John S Stafford IIIMajor ShareholderSell10,000$23.06$230,600.00View SEC Filing  
8/11/2016John S Stafford IIIMajor ShareholderSell30,500$21.87$667,035.00View SEC Filing  
8/10/2016Edgardo Baracchini JrInsiderSell2,500$21.83$54,575.00View SEC Filing  
8/3/2016Edgardo Baracchini, Jr.InsiderSell4,528$20.00$90,560.00View SEC Filing  
8/3/2016John R. DesjarlaisVPSell5,905$20.00$118,100.00View SEC Filing  
7/11/2016Edgardo Baracchini JrInsiderSell1,250$18.13$22,662.50View SEC Filing  
6/28/2016Edgardo Baracchini JrInsiderSell1,250$15.10$18,875.00View SEC Filing  
5/24/2016Bassil I DahiyatCEOSell45,886$13.00$596,518.00View SEC Filing  
4/7/2016Edgardo Baracchini JrInsiderSell3,750$15.00$56,250.00View SEC Filing  
3/17/2016Bassil I DahiyatCEOSell45,886$11.02$505,663.72View SEC Filing  
3/3/2016John R DesjarlaisVPSell14,260$12.01$171,262.60View SEC Filing  
2/1/2016John S Stafford IIIMajor ShareholderSell25$10.79$269.75View SEC Filing  
1/29/2016John S Stafford IIIMajor ShareholderBuy25$10.83$270.75View SEC Filing  
1/4/2016John R. DesjarlaisVPSell1,100$14.13$15,543.00View SEC Filing  
12/17/2015John J KuchVPSell4,781$14.89$71,189.09View SEC Filing  
12/16/2015Paul A. FosterinsiderSell6,025$15.01$90,435.25View SEC Filing  
12/3/2015John S. Stafford IIIDirectorSell30,000$15.13$453,900.00View SEC Filing  
11/25/2015Edgardo Baracchini, Jr.insiderSell2,500$15.00$37,500.00View SEC Filing  
9/3/2015John S Stafford IIIDirectorSell10,000$17.22$172,200.00View SEC Filing  
9/1/2015Edgardo Baracchini, Jr.insiderSell1,250$16.49$20,612.50View SEC Filing  
7/6/2015John S Stafford IIIDirectorSell10,000$22.29$222,900.00View SEC Filing  
7/1/2015Edgardo Baracchini JrInsiderSell2,500$22.24$55,600.00View SEC Filing  
6/16/2015John S Stafford IIIDirectorSell20,000$20.35$407,000.00View SEC Filing  
6/15/2015Bruce L A CarterDirectorSell10,000$19.21$192,100.00View SEC Filing  
6/15/2015Edgardo Baracchini JrInsiderSell1,277$19.85$25,348.45View SEC Filing  
6/12/2015John J KuchVPSell8,756$19.35$169,428.60View SEC Filing  
6/12/2015John S Stafford IIIDirectorSell250,000$19.00$4,750,000.00View SEC Filing  
6/3/2015John S Stafford IIIDirectorSell10,000$18.76$187,600.00View SEC Filing  
6/1/2015Edgardo Baracchini JrInsiderSell1,250$18.14$22,675.00View SEC Filing  
5/26/2015John S Stafford IIIDirectorSell10,000$17.01$170,100.00View SEC Filing  
5/15/2015Edgardo Baracchini JrInsiderSell1,604$15.00$24,060.00View SEC Filing  
8/11/2014John S Stafford IIIDirectorSell124,000$9.37$1,161,880.00View SEC Filing  
12/6/2013John S Stafford IIIDirectorBuy275,000$5.50$1,512,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Xencor (NASDAQ XNCR)

Source:
DateHeadline
Head-To-Head Contrast: Xencor (XNCR) vs. Its CompetitorsHead-To-Head Contrast: Xencor (XNCR) vs. Its Competitors
www.americanbankingnews.com - November 17 at 3:30 PM
Xencor, Inc. (XNCR) Major Shareholder John S. Stafford III Purchases 3,400 SharesXencor, Inc. (XNCR) Major Shareholder John S. Stafford III Purchases 3,400 Shares
www.americanbankingnews.com - November 13 at 6:26 PM
Xencor, Inc. (XNCR) Stock Rating Reaffirmed by Piper Jaffray CompaniesXencor, Inc. (XNCR) Stock Rating Reaffirmed by Piper Jaffray Companies
www.americanbankingnews.com - November 13 at 2:29 PM
Xencor, Inc. (XNCR) Cut to Sell at Zacks Investment ResearchXencor, Inc. (XNCR) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - November 11 at 10:22 AM
Wedbush Weighs in on Xencor, Inc.s FY2017 Earnings (XNCR)Wedbush Weighs in on Xencor, Inc.'s FY2017 Earnings (XNCR)
www.americanbankingnews.com - November 10 at 12:26 PM
Xencor, Inc. (XNCR) Expected to Earn FY2017 Earnings of ($1.04) Per ShareXencor, Inc. (XNCR) Expected to Earn FY2017 Earnings of ($1.04) Per Share
www.americanbankingnews.com - November 10 at 12:26 PM
Your Daily Pharma Scoop: Portola Upside, Novartis Reports Positive Cosentyx Data, Keryx TumblesYour Daily Pharma Scoop: Portola Upside, Novartis Reports Positive Cosentyx Data, Keryx Tumbles
seekingalpha.com - November 9 at 10:29 AM
Edited Transcript of XNCR earnings conference call or presentation 7-Nov-17 9:30pm GMTEdited Transcript of XNCR earnings conference call or presentation 7-Nov-17 9:30pm GMT
finance.yahoo.com - November 9 at 10:29 AM
Xencor to Present Preclinical Data on Tumor Microenvironment Targeting Bispecifics XmAb®20717 and XmAb®23104 at Society for Immunotherapy of Cancer (SITC) 2017 Annual MeetingXencor to Present Preclinical Data on Tumor Microenvironment Targeting Bispecifics XmAb®20717 and XmAb®23104 at Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting
finance.yahoo.com - November 9 at 10:29 AM
Xencor reports 3Q lossXencor reports 3Q loss
finance.yahoo.com - November 7 at 9:15 PM
Xencor, Inc. to Host Earnings CallXencor, Inc. to Host Earnings Call
finance.yahoo.com - November 7 at 4:10 PM
Xencor Reports Third Quarter 2017 Financial Results and Provides Clinical Pipeline UpdateXencor Reports Third Quarter 2017 Financial Results and Provides Clinical Pipeline Update
finance.yahoo.com - November 7 at 4:10 PM
Xencor Presents Final Results from Phase 2 Study of XmAb®5871 in IgG4-Related Disease (IgG4-RD) at the American College of Rheumatology 2017 Annual MeetingXencor Presents Final Results from Phase 2 Study of XmAb®5871 in IgG4-Related Disease (IgG4-RD) at the American College of Rheumatology 2017 Annual Meeting
finance.yahoo.com - November 5 at 8:22 AM
Xencor, Inc. (XNCR) Receives Consensus Rating of "Hold" from AnalystsXencor, Inc. (XNCR) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - November 2 at 7:42 PM
Xencor, Inc. (XNCR) Major Shareholder Buys $271,397.00 in StockXencor, Inc. (XNCR) Major Shareholder Buys $271,397.00 in Stock
www.americanbankingnews.com - November 2 at 5:40 PM
John S. Stafford III Purchases 50,000 Shares of Xencor, Inc. (XNCR) StockJohn S. Stafford III Purchases 50,000 Shares of Xencor, Inc. (XNCR) Stock
www.americanbankingnews.com - November 2 at 5:20 PM
Xencor to Host Third Quarter 2017 Financial Results Webcast and Conference Call on November 7, 2017Xencor to Host Third Quarter 2017 Financial Results Webcast and Conference Call on November 7, 2017
finance.yahoo.com - October 31 at 12:30 PM
John S. Stafford III Buys 24,653 Shares of Xencor, Inc. (XNCR) StockJohn S. Stafford III Buys 24,653 Shares of Xencor, Inc. (XNCR) Stock
www.americanbankingnews.com - October 27 at 8:40 PM
Insider Buying: Xencor, Inc. (XNCR) Major Shareholder Purchases 150,000 Shares of StockInsider Buying: Xencor, Inc. (XNCR) Major Shareholder Purchases 150,000 Shares of Stock
www.americanbankingnews.com - October 27 at 8:22 PM
Analyzing Xencor (XNCR) and The CompetitionAnalyzing Xencor (XNCR) and The Competition
www.americanbankingnews.com - October 25 at 8:36 AM
Xencor, Inc. – Value Analysis (NASDAQ:XNCR) : October 23, 2017Xencor, Inc. – Value Analysis (NASDAQ:XNCR) : October 23, 2017
finance.yahoo.com - October 24 at 12:46 PM
Xencor, Inc. (XNCR) Given a $36.00 Price Target at Canaccord GenuityXencor, Inc. (XNCR) Given a $36.00 Price Target at Canaccord Genuity
www.americanbankingnews.com - October 23 at 6:20 PM
DBVT Disappoints, GSK Gets Greenlight, AIMT Catches Eyes, FDA Snubs ATRSDBVT Disappoints, GSK Gets Greenlight, AIMT Catches Eyes, FDA Snubs ATRS
www.rttnews.com - October 23 at 9:15 AM
Xencor (XNCR) Plans to Present Final Results from Phase 2 Study of XmAb5871 in IgG4-Related Disease at ACRXencor (XNCR) Plans to Present Final Results from Phase 2 Study of XmAb5871 in IgG4-Related Disease at ACR
www.streetinsider.com - October 21 at 10:02 AM
Xencor to Present Final Results from Phase 2 Study of XmAb®5871 in IgG4-Related Disease at American College of Rheumatology (ACR) 2017 Annual MeetingXencor to Present Final Results from Phase 2 Study of XmAb®5871 in IgG4-Related Disease at American College of Rheumatology (ACR) 2017 Annual Meeting
finance.yahoo.com - October 21 at 10:02 AM
Xencor, Inc. breached its 50 day moving average in a Bearish Manner : XNCR-US : October 20, 2017Xencor, Inc. breached its 50 day moving average in a Bearish Manner : XNCR-US : October 20, 2017
finance.yahoo.com - October 20 at 10:37 AM
Xencor, Inc. (XNCR) Receives Average Rating of "Hold" from BrokeragesXencor, Inc. (XNCR) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - October 8 at 4:42 PM
-$0.29 Earnings Per Share Expected for Xencor, Inc. (XNCR) This Quarter-$0.29 Earnings Per Share Expected for Xencor, Inc. (XNCR) This Quarter
www.americanbankingnews.com - October 4 at 2:36 PM
Xencor, Inc. :XNCR-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017Xencor, Inc. :XNCR-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017
finance.yahoo.com - September 19 at 9:51 AM
Xencor, Inc. (XNCR) Expected to Announce Quarterly Sales of $8.15 MillionXencor, Inc. (XNCR) Expected to Announce Quarterly Sales of $8.15 Million
www.americanbankingnews.com - September 17 at 5:48 AM
Xencor, Inc. (XNCR) Receives Consensus Recommendation of "Hold" from BrokeragesXencor, Inc. (XNCR) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - September 13 at 6:43 PM
Xencor, Inc. breached its 50 day moving average in a Bullish Manner : XNCR-US : September 11, 2017Xencor, Inc. breached its 50 day moving average in a Bullish Manner : XNCR-US : September 11, 2017
finance.yahoo.com - September 12 at 12:26 PM
Xencor, Inc. (XNCR) Major Shareholder John S. Stafford III Buys 41,016 SharesXencor, Inc. (XNCR) Major Shareholder John S. Stafford III Buys 41,016 Shares
www.americanbankingnews.com - August 23 at 7:44 PM
Xencor, Inc. (XNCR) Given Consensus Rating of "Hold" by BrokeragesXencor, Inc. (XNCR) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - August 19 at 4:46 PM
Insider Buying: Xencor, Inc. (XNCR) Major Shareholder Purchases 25,000 Shares of StockInsider Buying: Xencor, Inc. (XNCR) Major Shareholder Purchases 25,000 Shares of Stock
www.americanbankingnews.com - August 18 at 7:46 PM
Xencor, Inc. (XNCR) Major Shareholder John S. Stafford III Purchases 43,500 SharesXencor, Inc. (XNCR) Major Shareholder John S. Stafford III Purchases 43,500 Shares
www.americanbankingnews.com - August 18 at 7:46 PM
Insider Buying: Xencor, Inc. (XNCR) Major Shareholder Purchases 79,035 Shares of StockInsider Buying: Xencor, Inc. (XNCR) Major Shareholder Purchases 79,035 Shares of Stock
www.americanbankingnews.com - August 18 at 7:26 PM
Xencor, Inc. – Value Analysis (NASDAQ:XNCR) : August 17, 2017Xencor, Inc. – Value Analysis (NASDAQ:XNCR) : August 17, 2017
finance.yahoo.com - August 17 at 9:30 AM
Xencor, Inc. (XNCR) Major Shareholder John S. Stafford III Purchases 27,000 SharesXencor, Inc. (XNCR) Major Shareholder John S. Stafford III Purchases 27,000 Shares
www.americanbankingnews.com - August 14 at 10:46 PM
FY2017 EPS Estimates for Xencor, Inc. (XNCR) Lifted by AnalystFY2017 EPS Estimates for Xencor, Inc. (XNCR) Lifted by Analyst
www.americanbankingnews.com - August 11 at 10:14 AM
See what the IHS Markit Score report has to say about Xencor Inc.See what the IHS Markit Score report has to say about Xencor Inc.
finance.yahoo.com - August 11 at 9:20 AM
Q3 2017 Earnings Forecast for Xencor, Inc. Issued By Leerink Swann (NASDAQ:XNCR)Q3 2017 Earnings Forecast for Xencor, Inc. Issued By Leerink Swann (NASDAQ:XNCR)
www.americanbankingnews.com - August 10 at 7:56 AM
-$0.27 Earnings Per Share Expected for Xencor, Inc. (XNCR) This Quarter-$0.27 Earnings Per Share Expected for Xencor, Inc. (XNCR) This Quarter
www.americanbankingnews.com - August 10 at 12:32 AM
Canaccord Genuity Reaffirms "Buy" Rating for Xencor, Inc. (XNCR)Canaccord Genuity Reaffirms "Buy" Rating for Xencor, Inc. (XNCR)
www.americanbankingnews.com - August 9 at 12:38 AM
Xencor, Inc. (XNCR) Releases Quarterly  Earnings Results, Beats Expectations By $0.10 EPSXencor, Inc. (XNCR) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPS
www.americanbankingnews.com - August 8 at 10:47 AM
Xencor Reports Second Quarter 2017 Financial ResultsXencor Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 8 at 8:28 AM
Xencor reports 2Q lossXencor reports 2Q loss
finance.yahoo.com - August 8 at 8:28 AM
Edited Transcript of XNCR earnings conference call or presentation 7-Aug-17 8:30pm GMTEdited Transcript of XNCR earnings conference call or presentation 7-Aug-17 8:30pm GMT
finance.yahoo.com - August 8 at 8:28 AM
Xencor, Inc. breached its 50 day moving average in a Bearish Manner : XNCR-US : August 3, 2017Xencor, Inc. breached its 50 day moving average in a Bearish Manner : XNCR-US : August 3, 2017
finance.yahoo.com - August 4 at 10:12 AM
Xencor to Present at Upcoming Investor ConferencesXencor to Present at Upcoming Investor Conferences
finance.yahoo.com - August 2 at 8:54 AM

Social Media

Financials

Chart

Xencor (NASDAQ XNCR) Chart for Monday, November, 20, 2017
Loading chart…

This page was last updated on 11/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.